Contents

Search

lisproinsulin (Humalog, Lispro, Admelog, HumaPenn Memoir, HumaPenn Luxura HD, Humalog U-200 KwikPen)

Synthetic proinsulin with more rapid onset & shorter duration of action than regular insulin. Humalog Mix 75/25: - 75% neutral protamine lispro (NPL) - 25% insulin lispro Indications: - diabetes mellitus* - diabetes mellitus type 1 - diabetes mellitus type 2 - gestational diabetes - hyperglycemia * patients who have excessive blood glucose increases 1-2 hours after meals with hypoglycemia 4-5 hours later Dosage: - injected 5-10 minutes before eating* * May need to increase morning dose of NPH to compensate for loss of 'tail' or persistence of regular insulin action Stable for 28 days refrigerated, 14 days at room temperature. HumaPenn Memoir is a reusable pen $100, $45 with coupon lasts 3 years HumaPenn Luxura HD measures Humalog in 1/2 units Humalog U-200 is an option for patients using > 20 units/day of rapid-acting insulin [6] Pharmacokinetics: 1) onset of action 15 minutes 2) peak 45 minutes 3) duration 3 hours [3] Notes: - copy cat version of Humolog (Admelog) approved Dec 2017 [7]

Interactions

drug adverse effects of hypoglycemic agents

General

short-acting insulin

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  2. Prescriber's Letter 7(6):33 2000
  3. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  4. Prescriber's Letter 14(4): 2007 Change in storage for Byetta and new insulin pens: HumaPen Memoir and HumaPen Luxura HD Detail-Document#: 230408 (subscription needed) http://www.prescribersletter.com
  5. Deprecated Reference
  6. Prescriber's Letter 22(8): 2015 (subscription needed) CHART: Comparison of Insulins and Injectable Diabetes Meds CHART: Tips to Improve Insulin Safety Detail-Document#: 310825 http://www.prescribersletter.com
  7. Tucker ME First Humalog Copycat (Admelog) Approved by FDA. Medscape - Dec 11, 2017. https://www.medscape.com/viewarticle/889893 - FDA News Release. December 11, 2017 FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm588466.htm